CNTX 6970

Drug Profile

CNTX 6970

Alternative Names: CNTX-6970

Latest Information Update: 11 Apr 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Non-opioid analgesics; Small molecules
  • Mechanism of Action Cytokine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammatory pain

Most Recent Events

  • 30 Mar 2016 Phase-I clinical trials in Inflammatory pain in USA (unspecified route)
  • 30 Mar 2016 Preclinical trials in Inflammatory pain in USA (unspecified route)
  • 30 Mar 2016 Centrexion Therapeutics acquires CNTX-6970 from Boehringer Ingelheim
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top